Continuous Readout versus Titer-Based Assays of Influenza Vaccine Trials: Sensitivity, Specificity, and False Discovery Rates

Table 1

Vaccination strategy of the DMID 08-0059 study.

		Days after vaccination with inactivated A/Indonesia/5/05 (A/Ind05)
Group	n	0	7	14	28	35	42	56	180/208
Primed	46	✕	✕	✕	✕			✕	✕
Multiple boost	16	✕	✕	✕	✕			✕	✕
Unprimed	31	✕	✕	✕	✕	✕	✕	✕	✕

Note: “✕” denotes that blood samples were collected before vaccination (day 0) and on days 7, 14, 28, 56, and 180 after vaccination. For the unprimed group, blood samples were collected before vaccination (day 0), on days 7, 14, and 28 before boosting, on day 28, and then on days 7 (day 35), 14 (day 42), 28 (day 56), and 180 (day 208) after boosting. Both the primed and the multiple boost groups had received the inactivated subvirion influenza A/Vietnam/1203/04 (A/Vie04) vaccine in 2005-2006. In addition, the multiple primed group also had received the baculovirus expressed recombinant influenza A/Hong Kong/156/97 vaccine (A/HK97) in 1997-1998. The unprimed group received only the A/Ind05 vaccine and a second booster vaccination at 28 days.